<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058835</url>
  </required_header>
  <id_info>
    <org_study_id>Pro20150001562</org_study_id>
    <secondary_id>IN-US-276-1340</secondary_id>
    <nct_id>NCT03058835</nct_id>
  </id_info>
  <brief_title>IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration Project</brief_title>
  <official_title>IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this study is to assess attitudes toward PrEP, feasibility of Truvada PrEP&#xD;
      procurement through the established access procedures, and adherence to Truvada PrEP among US&#xD;
      women at risk for HIV acquisition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:&#xD;
&#xD;
      This is a 24 week prospective pilot study assessing attitudes toward and feasibility of using&#xD;
      Truvada PrEP in a population of women at risk for HIV acquisition.At this site 31 HIV-&#xD;
      uninfected women desiring PrEP will be enrolled at each site (confirm number). We will have&#xD;
      to consent about 50 women which includes screen failures.The study will assess attitudes&#xD;
      towards and adherence to PrEP with questionnaires at weeks 12 and 24. Tenofovir levels&#xD;
      procured at week 12 and 24 week of PrEP will be used to assess adherence to PrEP.&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
        1. Describe attitudes toward PrEP among a population of women at risk for HIV acquisition,&#xD;
           living in HIV prevalent areas.&#xD;
&#xD;
        2. Assess feasibility of Truvada procurement through the established Gilead access program&#xD;
&#xD;
        3. Evaluate adherence at week 12 and week 24 using dried blood spots&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
        1. Describe HIV incidence&#xD;
&#xD;
        2. Describe associations of positive and negative attitudes toward PrEP with acceptance of&#xD;
           PrEP and subsequent adherence&#xD;
&#xD;
        3. Assess adherence at weeks 12 and 24&#xD;
&#xD;
        4. Evaluate the relationship between PrEP adherence and sexual activity&#xD;
&#xD;
        5. Compare geographic areas with respect to PrEP attitudes&#xD;
&#xD;
        6. Mentor junior investigators at each site.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Describe attitudes toward PrEP among a population of women at risk for HIV acquisition, living in HIV prevalent areas</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Attitudes towards PrEP will be assessed with questionnaires at weeks 12 and 24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess feasibility of Truvada procurement through the established Gilead access program</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Logistic regression comparing the proportion of participants with tenofovir plasma levels greater than 0.3 will be analyzed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate adherence to Truvada PrEP at week 12 and week 24 using dried blood spots</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Adherence to Truvada PrEP will be assessed at week 12 and week 24 using dried blood spots and questionnaire responses concerning adherence to PrEP</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>PrEP Adherence Monitoring</condition>
  <arm_group>
    <arm_group_label>PrEP with Truvada</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study participants will be assigned to this arm and will receive Truvada tablets (tenofovir disoproxil and emtricitabine) for PrEP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir disoproxil and emtricitabine</intervention_name>
    <description>Pre-exposure Prophylaxis with Truvada will be distributed to all participants eligible to receive PrEP.</description>
    <arm_group_label>PrEP with Truvada</arm_group_label>
    <other_name>Truvada tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 - 64 years old&#xD;
&#xD;
          -  Able to give consent&#xD;
&#xD;
          -  &quot;At risk&quot; for HIV as defined by any of the following:&#xD;
&#xD;
               1. unprotected sex (in past 6 months) with 1 or more men of unknown HIV status&#xD;
&#xD;
               2. evaluated for an STI within 6 months prior to screening&#xD;
&#xD;
               3. sex in last 6 months with an HIV-infected partner&#xD;
&#xD;
               4. IDU with report of using previously used or shared needles in past 6 months or&#xD;
                  has been in a methadone, buprenorphine, or suboxone treatment program in past 6&#xD;
                  months or engaging in high-risk sexual behaviors&#xD;
&#xD;
               5. individuals engaging in transactional sex (i.e sex for money, drugs, or housing)&#xD;
&#xD;
               6. Infrequently uses condoms during sex with 1 or more partners of unknown HIV&#xD;
                  status who are known to be at substantial risk of HIV infection (IDU or bisexual&#xD;
                  male partner)&#xD;
&#xD;
          -  CrCl â‰¥ 60 ml/min&#xD;
&#xD;
          -  HIV- uninfected women desiring PrEP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active alcohol or drug use or dependence which may interfere with adherence to study&#xD;
             requirements&#xD;
&#xD;
          -  HIV-infected at screening or enrollment&#xD;
&#xD;
          -  Estimated CrCl &lt; 60 mL/min&#xD;
&#xD;
          -  Past participation in an HIV vaccine study&#xD;
&#xD;
          -  Positive Hepatitis B surface antigen test&#xD;
&#xD;
          -  Underlying medical condition with survival unlikely during follow-up period&#xD;
&#xD;
          -  Any condition that in the opinion of study staff would make participation in the study&#xD;
             unsafe or interfere with achieving study objectives&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Actively trying to achieve pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shobha Swaminathan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New Jersey Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marta Paez-Quinde</last_name>
    <phone>973-972-3810</phone>
    <email>paezqumv@njms.rutgers.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rondalya Deshields</last_name>
    <phone>973-972-3729</phone>
    <email>deshierd@njms.rutgers.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School Clinical Research Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Wilkinson</last_name>
      <phone>304-293-4488</phone>
      <email>samuel.wilkinson@mail.wvu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lacey Kelley, BSN</last_name>
      <phone>304-276-3828</phone>
      <email>lkelley5@hsc.wvu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Judith Feinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Shobha Swaminathan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Truvada</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

